FindTrial
Sign In

Transcutaneous Auricular Vagus Nerve Stimulation for Prevention of Postpartum Depressive Symptoms in Women Undergoing Elective Cesarean Section: A Prospective, Double-Blind, Randomized Controlled Trial

Transcutaneous Auricular Vagus Nerve Stimulation for Prevention of Postpartum Depressive Symptoms in Women Undergoing Elective Cesarean Section: A Prospective, Double-Blind, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120743
Enrollment
Unknown
Registered
2026-03-19
Start date
2026-03-23
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Depressive Symptoms

Interventions

Experimental Group:In the experimental group, patients received transcutaneous auricular vagus nerve stimulation. The left cymba conchae was stimulated, targeting the auricular branch of the vagus ner
Control Group:In the control group, stimulation electrodes were placed at the corresponding sites. After brief intensity adjustment with the device turned on, the device was turned off, and 30 minutes

Sponsors

The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Maternal age >= 18 years, singleton pregnancy at 37–42 weeks of gestation. 2. Scheduled for cesarean section under combined spinal-epidural anesthesia. 3. Planned for transverse lower uterine segment incision. 4. ASA physical status II or III.

Exclusion criteria

Exclusion criteria: 1. Refusal to provide written informed consent. 2. Current or previous history of neurological or psychiatric disorders. 3. Otitis or dermatitis of the ear. 4. History of substance abuse. 5. Cognitive impairment or inability to communicate. 6. Inability to use patient-controlled intravenous analgesia (PCIA). 7. Severe gestational hypertension, diabetes mellitus, or cardiovascular/cerebrovascular diseases.

Design outcomes

Primary

MeasureTime frame
The positive rate of PDD screening on postpartum day 7;—

Secondary

MeasureTime frame
Postpartum anxiety;Postpartum pain;Postpartum sleep quality;Postoperative rescue analgesics;Postoperative urinary retention;Gastrointestinal function recovery;Postoperative analgesic pump consumption;—

Countries

China

Contacts

Public ContactCao Junli

The Affiliated Hospital of Xuzhou Medical University

caojl0310@aliyun.com+86 516 8326 2686

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026